P/E at 35.12 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Above Industry Average

The stock’s P/E ratio of 35.12 stands approximately 10.1% higher than the sector average of 31.90, signalling that investors are willing to pay a premium for Sun Pharmaceutical Industries Ltd relative to its peers. This premium may reflect expectations of superior earnings growth or a perception of stronger fundamentals compared to the broader Pharmaceuticals & Biotechnology sector. However, such a valuation gap also raises questions about sustainability, especially given the sector’s mixed result performance so far in the current reporting season.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a complex momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has declined by 1.05%, outperforming the Sensex’s 4.89% fall during the same period. The one-month and three-month returns are positive at 1.91% and 0.57% respectively, contrasting sharply with the Sensex’s steep declines of 12.18% and 14.47% over these intervals. Year-to-date, the stock has gained 2.64%, again outperforming the Sensex’s negative 14.17%. This relative strength in the short to medium term suggests resilience amid broader market weakness — Sun Pharmaceutical Industries Ltd’s sector outperformance is notable given the sector’s mixed results, with 16 positive, 9 flat, and 9 negative declarations among 34 stocks so far.

However, the stock’s one-day and one-week performances show slight underperformance, with declines of 0.69% and 0.97% respectively, though these losses are less severe than the Sensex’s drops of 1.86% and 3.12%. This suggests some short-term profit-taking or consolidation after recent gains — is this a temporary pause or a sign of shifting investor sentiment? The data points to a stock that has weathered recent volatility better than the broader market but is not immune to short-term fluctuations.

Moving Average Configuration: Mixed Technical Signals

The technical setup of Sun Pharmaceutical Industries Ltd reveals a nuanced picture. The stock is trading above its 50-day, 100-day, and 200-day moving averages, indicating a medium to long-term bullish trend. However, it remains below its 5-day and 20-day moving averages, suggesting some short-term weakness or consolidation. This configuration often points to a recent pullback within an overall uptrend — is this a genuine recovery or a dead-cat bounce? The proximity to its 52-week high, just 4.47% away, further supports the notion of underlying strength despite short-term hesitation.

Sector Context: Mixed Results Amidst Large-Cap Stability

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results with 16 stocks reporting positive outcomes, 9 flat, and 9 negative among 34 declarations so far. Within this environment, Sun Pharmaceutical Industries Ltd’s relative outperformance and premium valuation stand out. The sector’s overall volatility contrasts with the stock’s steadier performance, highlighting its large-cap status and market leadership. With a market capitalisation of ₹4,23,530.61 crores, it remains one of the dominant players in the space, which may partly explain its valuation premium.

Rating Context: Previously Rated Hold, Now Reassessed

On 23 Feb 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from a previous Hold rating by MarketsMOJO. While the current rating is not disclosed, the reassessment reflects a fresh analysis of the company’s fundamentals, valuation, and technicals. The stock’s Mojo Score of 72.0 indicates a solid standing within the Pharmaceuticals & Biotechnology sector, but the valuation premium and mixed short-term momentum suggest a nuanced outlook — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Stock Balancing Premium Valuation and Mixed Momentum

The data on Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a premium valuation relative to its sector, supported by a solid Mojo Score and a history of outperformance over the Sensex in several timeframes. The mixed signals from short-term moving averages and recent price action suggest some caution, but the stock’s position above key long-term moving averages and proximity to its 52-week high indicate underlying strength. The sector’s mixed results further contextualise the stock’s performance, highlighting its relative resilience.

Investors analysing this stock must weigh the valuation premium against the recent momentum and technical configuration — what is the current rating for Sun Pharmaceutical Industries Ltd and how should it influence portfolio decisions?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →